PL EN


Preferences help
enabled [disable] Abstract
Number of results
2008 | 49 | 2 | 201-203
Article title

Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene

Content
Title variants
Languages of publication
EN
Abstracts
EN
Point mutations of bcr-abl tyrosine kinase are the most frequent causes of imatinib resistance in chronic myeloid leukaemia (CML) patients. In most CML cases with BCR-ABL mutations leading to imatinib resistance the second generation of tyrosine kinase inhibitors (TKI- e.g. nilotinib or dasatinib) may be effective. Here, we report a case of a CML patient who during imatinib treatment did not obtain clinical and cytogenetic response within 12 months of therapy. The sequencing of BCR-ABL kinase domains was performed and revealed the presence of a F359I point mutation (TTC-to-ATC nucleotide change leading to Phe-to-Ile amino acid substitution). After 1 month of nilotinib therapy a rapid progression of clinical symptoms was observed. In the presence of the F359I point mutation only dasatinib treatment overcame imatinib and nilotinib resistance.
Discipline
Year
Volume
49
Issue
2
Pages
201-203
Physical description
References
Document Type
ARTICLE
Publication order reference
Marta Baranska, Department of Hematology, Poznan University of Medical Sciences, Szamarzewskiego 84, 60?569 Poznan, Poland
YADDA identifier
bwmeta1.element.element-from-psjc-400371fb-8088-3f9c-9f47-439cf11882e1
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.